Whether or not heterozygous carriers of partial deficiencies of rare coagulation defects exhibit a bleeding tendency is an open issue.1,2 This issue is critical for our understanding of the need (or lack of need) for replacement therapy when these patients undergo surgery or other invasive procedures. Recently in this journal Ivaskevicius et al.,3 in their elegant description of several mutations of the gene encoding the factor XIII A submit, report that 8 of their 12 heterozygous patients, with plasma factor XIII levels ranging from 23% to 71%, had bleeding symptoms at the time of provocative events such as trauma, dental extractions, parturition or surgery. Spontaneous bleeding in mucosal tracts (menorrhagia, unspecified mucosal bleeding) is also reported.3 As a result of their findings, the authors recommend carrying out a quantitative assay of factor XIII activity in people referred because of a positive clinical history of postoperative bleeding.3 I believe that this recommendation is premature on the basis of the evidence presented in the publication. It is well established that significant bleeding symptoms may occur also in normal people,4,5 and none were included as controls in the study of Ivaskevicius et al.3 Moreover, the evidence gained by observing the relationship between the occurrence of bleeding symptoms and the levels of factor XIII attained in homozygotes kept prophylactically on regular replacement therapy indicates that trough plasma levels as low as 3% to 10% are sufficient to keep these severely affected patients free from bleeding.6 Bleeding symptoms in people with levels of factor XIII higher than 10% have only been reported in the frame of a questionnaire survey7 that had inherent limits in terms of an accurate correlation between clinical manifestations and laboratory phenotype. The findings of Ivaskevicius et al.3 and others1,2 also emphasize the need to develop a score specific for patients with rare coagulation disorders, which should help to draw a more precise line between bleeders and non-bleeders.
References
- Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004; 104(5):1243-52. PubMedhttps://doi.org/10.1182/blood-2004-02-0595Google Scholar
- Acharya SS, Coughlin A, Dimichele DM, Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004; 2(2):248-56. PubMedhttps://doi.org/10.1111/j.1538-7836.2003.t01-1-00553.xGoogle Scholar
- Ivaskevicius V, Biswas A, Bevans C, Schroeder V, Kohler HP, Rott H. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica. 2010; 95(6):956-62. PubMedhttps://doi.org/10.3324/haematol.2009.017210Google Scholar
- Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost. 1988; 59(3):349-52. PubMedGoogle Scholar
- Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995; 155(3):1409-15. PubMedhttps://doi.org/10.1001/archinte.1995.00430130095010Google Scholar
- Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. 1999; 107(3):468-84. PubMedhttps://doi.org/10.1046/j.1365-2141.1999.01648.xGoogle Scholar
- Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. Semin.Thromb.Hemost. 1996; 22(5):415-8. Google Scholar